Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

Corrigendum: CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

Bibliographic Details
Main Authors:	Laurence McEvoy, Joanne Cliff, Daniel F Carr, Andrea Jorgensen, Rosemary Lord, Munir Pirmohamed
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Pharmacology
Subjects:	chemotherapy cytochrome P450 peripheral neuropathy personalised medicine pharmacogenetics
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1274075/full

Similar Items

CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study
by: Laurence McEvoy, et al.
Published: (2023-07-01)

CYP2C19 genetic polymorphism in the Vietnamese population
by: Nhung Phuong Vu, et al.
Published: (2019-08-01)

The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank
by: Win Lee Edwin Wong, et al.
Published: (2023-09-01)

Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review
by: Bradley Roberts, et al.
Published: (2023-09-01)

Genetic Polymorphisms in CYP2 Gene Family in Bulgarian Individuals and their Clinical Implications
by: Yovinska S., et al.
Published: (2024-03-01)

Association of polymorphism of CYP2D6 and CYP2C9 genes encoding P-450 proteins of cytochrome with arterial hypertension
by: Saratsev A.V., et al.
Published: (2012-12-01)

“Late” Withdrawal Syndrome after Carbamazepine In Utero Exposure in a CYP2C9 Slow Metabolizer Newborn
by: Caroline F. Samer, et al.
Published: (2017-04-01)

Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina
by: Vidović Stojko, et al.
Published: (2021-06-01)

Pathway-targeted pharmacogenomics of CYP1A2 in human liver
by: Kathrin eKlein, et al.
Published: (2010-11-01)

Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula
by: Francesco Carano, et al.
Published: (2018-01-01)

CYP2D6 Genotype-Based Dose Recommendations for Risperidone in Asian People
by: Yuanxia Cui, et al.
Published: (2020-08-01)

Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations
by: Sychev DA, et al.
Published: (2017-03-01)

Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina
by: Sabina Semiz, et al.
Published: (2011-02-01)

e-PKGene: A knowledge-based research tool for analysing the impact of genetics on drug exposure
by: Hachad Houda, et al.
Published: (2011-07-01)

Genetic polymorphisms and drug metabolism
by: Vita Dolžan
Published: (2007-12-01)

Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients
by: Carrascal-Laso L, et al.
Published: (2021-08-01)

The Human Cytochrome P450 (<it>CYP</it>) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects
by: Sim Sarah C, et al.
Published: (2010-04-01)

Association of CYP2C9*2 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population
by: Asif Jan, et al.
Published: (2023-08-01)

Frequency of CYP2D6 Alleles Including Structural Variants in the United States
by: Andria L. Del Tredici, et al.
Published: (2018-04-01)

Pharmacogenomics of cytochrome P450 3A4 (CYP3A4): recent progress towards the missing heritability problem
by: Kathrin eKlein, et al.
Published: (2013-02-01)

Genetic diversity of CYP3A5 and ABCB1 variants in East-Central and South European populations
by: Grazyna Adler, et al.
Published: (2022-05-01)

CYP2C19 and CYP2D6 Genotypes and Metabolizer Status Distribution in a Bulgarian Psychiatric Cohort
by: Hristo Y. Ivanov, et al.
Published: (2022-07-01)

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes
by: Julia Carolin Stingl, et al.
Published: (2022-12-01)

CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort
by: Dagostino C, et al.
Published: (2018-10-01)

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
by: N Fleeman, et al.
Published: (2010-01-01)

The Effects of Cumulative Dose and Polymorphisms in CYP2B6 on the Mitotane Plasma Trough Concentrations in Chinese Patients With Advanced Adrenocortical Carcinoma
by: Xin Liu, et al.
Published: (2022-06-01)

Practice of CYP450 genotyping and phenotyping in children in a real-life setting
by: Frédérique Rodieux, et al.
Published: (2023-02-01)

Pharmacogenetics of schizophrenia in real clinical practice: a clinical case
by: R. F. Nasyrova, et al.
Published: (2018-12-01)

Pharmacogenetics of Praziquantel Metabolism: Evaluating the Cytochrome P450 Genes of Zimbabwean Patients During a Schistosomiasis Treatment
by: Grace Zdesenko, et al.
Published: (2022-06-01)

A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in <i>CYP3A4</i>, <i>CYP3A5</i>, <i>CYP1A2</i>, <i>CYP2C9</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>ABCB1,</i> and <i>VKORC1</i> Genes
by: Camille Tron, et al.
Published: (2022-05-01)

Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study
by: AL-Eitan LN, et al.
Published: (2019-09-01)

Metformin represses drug – induced expression of CYP2B6 by the constitutive androstane receptor phosphorylation
Published: (2014-10-01)

Optimization of the CYP inhibition assay using LC-MS/MS
by: Muhammad Asyraf Abduraman, et al.
Published: (2022-01-01)

Next-Generation Sequencing and Bioinformatics-Based Protocol for the Full-Length CYP2E1 Gene Polymorphism Analysis
by: Igumnova V, et al.
Published: (2022-11-01)

The Challenge and Importance of Integrating Drug–Nutrient–Genome Interactions in Personalized Cardiovascular Healthcare
by: Ioannis Stouras, et al.
Published: (2022-03-01)

Case report: application of pharmacogenetics in the personalized treatment of an elderly patient with a major depressive episode
by: Milica Pjevac, et al.
Published: (2023-08-01)

Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
by: Gina Mejía-Abril, et al.
Published: (2021-04-01)

Clinical <i>CYP2D6</i> Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
by: Tessa A. M. Mulder, et al.
Published: (2021-02-01)

Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway[S]
by: Robert Fischer, et al.
Published: (2014-06-01)

Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset
by: Jakob Sommer, et al.
Published: (2024-01-01)